Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 3
1963 2
1966 3
1968 3
1969 1
1971 1
1973 1
1974 1
1975 7
1976 14
1977 5
1978 5
1979 4
1980 1
1981 3
1982 7
1983 8
1984 4
1985 7
1986 12
1987 14
1988 8
1989 17
1990 14
1991 22
1992 30
1993 33
1994 32
1995 27
1996 39
1997 48
1998 60
1999 87
2000 87
2001 108
2002 117
2003 193
2004 228
2005 257
2006 318
2007 375
2008 447
2009 497
2010 590
2011 660
2012 778
2013 923
2014 1079
2015 1324
2016 1414
2017 1497
2018 1758
2019 2026
2020 2495
2021 2821
2022 3373
2023 3313
2024 3823
2025 2191
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29,761 results

Results by year

Filters applied: . Clear all
Page 1
Context-aware single-cell multiomics approach identifies cell-type-specific lung cancer susceptibility genes.
Long E, Yin J, Shin JH, Li Y, Li B, Kane A, Patel H, Sun X, Wang C, Luong T, Xia J, Han Y, Byun J, Zhang T, Zhao W, Landi MT, Rothman N, Lan Q, Chang YS, Yu F, Amos CI, Shi J, Lee JG, Kim EY, Choi J. Long E, et al. Among authors: han y. Nat Commun. 2024 Sep 12;15(1):7995. doi: 10.1038/s41467-024-52356-9. Nat Commun. 2024. PMID: 39266564 Free PMC article.
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.
Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, Xu J, Duan J, Wang Z, Wang K, Yu X, Zheng Q, Xu X, Hu G, Tan T, Yuan Y, Tian Z, Yan F, Han Y, Zhang J, Feng X. Pan J, et al. Among authors: han y. Nat Med. 2025 Jan;31(1):126-136. doi: 10.1038/s41591-024-03282-2. Epub 2024 Oct 1. Nat Med. 2025. PMID: 39354195 Clinical Trial.
KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy.
Guo J, Li N, Liu Q, Hao Z, Zhu G, Wang X, Wang H, Pan Q, Xu B, Han Y, Zhang G, Lian Y, Zhang W, Gu Y, Lin N, Zeng X, Jin Z, Lan W, Jiang J, Gao D, Dong L, Yuan H, Liang C, Qin J. Guo J, et al. Among authors: han y. Cancer Cell. 2025 Apr 22:S1535-6108(25)00139-4. doi: 10.1016/j.ccell.2025.04.002. Online ahead of print. Cancer Cell. 2025. PMID: 40280125
29,761 results
You have reached the last available page of results. Please see the User Guide for more information.